» Articles » PMID: 32460624

The Amount of Cytokine-release Defines Different Shades of Sars-Cov2 Infection

Overview
Specialty Biology
Date 2020 May 29
PMID 32460624
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The recent outbreak of coronavirus disease (COVID 19), spreading from China all around the world in early 2020, has led scientists to investigate the immuno-mediated mechanisms underlying the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) infection. Depending on the amount of cytokines released as the result of the immunological activation induced by SARS-CoV2, three major clinical phenotypes can be identified: "mild",symbolized as a "drizzle" of cytokines, severe as a "storm", and critical as a "hurricane". In patients with mild symptoms, the release of pro-inflammatory cytokines is balanced to obtain a defense response against the virus which is often self-limiting and overcomes without tissue damage. In severe phenotype, resembling a "cytokine-release syndrome", SARS-CoV2 causes the lysis of the immune-mediators leading to a cytokine storm able to induce lung epithelium damage and acute respiratory distress syndrome. In critical patients, the immune response may become uncontrolled, thus the cytokine burst resembles a form of secondary hemophagocytic lymphohistiocytosis which may result in a multi organ failure. In addition to the standard of care, an immune-modulatory therapy tailored to each one of the different phenotypes should be used in order to prevent or reduce the release of cytokines responsible for organ damage and disease progression.

Citing Articles

Inferring Recombination Events in SARS-CoV-2 Variants In Silico.

Najeeb N, Murukan A, Renjitha A, Jayaram M, Jabbar A, Haridasan H Adv Exp Med Biol. 2023; 1412:253-270.

PMID: 37378772 DOI: 10.1007/978-3-031-28012-2_14.


SARS-CoV-2 and HIV-1: So Different yet so Alike Immune Response at the Cellular and Molecular Level.

Demoliou C, Papaneophytou C, Nicolaidou V Int J Med Sci. 2022; 19(12):1787-1795.

PMID: 36313221 PMC: 9608044. DOI: 10.7150/ijms.73134.


Role of biological markers and CT severity score in predicting mortality in patients with COVID‑19: An observational retrospective study.

Todor S, Birlutiu V, Topircean D, Mihaila R Exp Ther Med. 2022; 24(5):698.

PMID: 36277141 PMC: 9535394. DOI: 10.3892/etm.2022.11634.


Time evolution of cytokine profiles associated with mortality in COVID-19 hospitalized patients.

Sanchez-de Prada L, Gorgojo-Galindo O, Fierro I, Martinez-Garcia A, de Quintana G, Gutierrez-Bustillo R Front Immunol. 2022; 13:946730.

PMID: 36238287 PMC: 9551198. DOI: 10.3389/fimmu.2022.946730.


Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection.

Kumar S, Dutta D, Ravichandiran V, Sukla S 3 Biotech. 2022; 12(9):227.

PMID: 35982759 PMC: 9383686. DOI: 10.1007/s13205-022-03281-5.


References
1.
Wong R, Wu A, To K, Lee N, Lam C, Wong C . Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003; 326(7403):1358-62. PMC: 162124. DOI: 10.1136/bmj.326.7403.1358. View

2.
Huang K, Su I, Theron M, Wu Y, Lai S, Liu C . An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2004; 75(2):185-94. PMC: 7166886. DOI: 10.1002/jmv.20255. View

3.
Garcia Borrega J, Godel P, Ruger M, Onur O, Shimabukuro-Vornhagen A, Kochanek M . In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere. 2019; 3(2):e191. PMC: 6746039. DOI: 10.1097/HS9.0000000000000191. View

4.
Hu C, Lu L, Wan J, Wen C . The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases. Curr Med Chem. 2017; 24(20):2241-2249. DOI: 10.2174/0929867324666170316115938. View

5.
Channappanavar R, Perlman S . Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017; 39(5):529-539. PMC: 7079893. DOI: 10.1007/s00281-017-0629-x. View